JGC
ACHV icon

J. Goldman & Co’s Achieve Life Sciences ACHV Stock Holding History

J. Goldman & Co’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-293,961
Closed -$785K – 440
2025
Q1 		$785K Buy
293,961
+269,413
+1,097% +$838K 0.02% 377
2024
Q4 		$86.4K Hold
24,548
– – ﹤0.01% 422
2024
Q3 		$116K Hold
24,548
– – ﹤0.01% 427
2024
Q2 		$115K Hold
24,548
– – ﹤0.01% 412
2024
Q1 		$112K Sell
24,548
-42,953
-64% -$191K ﹤0.01% 382
2023
Q4 		$278K Buy
+67,501
New +$294K 0.01% 290
2013
Q4 		– Sell
-40
Closed -$811K – 210
2013
Q3 		$811K Sell
40
-61
-60% -$1.26M 0.08% 211
2013
Q2 		$2.18M Buy
+101
New +$2.26M 0.22% 135

Other funds holding ACHV

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

J. Goldman & Co's ACHV Position: Q2 2025 in Review

J. Goldman & Co sold out of Achieve Life Sciences (ACHV) in Q2 2025, closing a stake of 293,961 shares — an estimated $785K sold.

J. Goldman & Co first reported a position in ACHV in Q2 2013 and held it in 8 quarters. The position peaked at $2.18M in Q2 2013. 65 funds tracked by Wall St. Rank hold ACHV as of Q2 2025.

  • J. Goldman & Co reported no remaining Achieve Life Sciences position as of Q2 2025 after selling out during the quarter.
  • J. Goldman & Co sold 293,961 Achieve Life Sciences shares in Q2 2025, an estimated $785K.
  • J. Goldman & Co first reported a position in Achieve Life Sciences in Q2 2013 and held it in 8 quarters.
  • J. Goldman & Co's Achieve Life Sciences position peaked at $2.18M in Q2 2013.
  • 65 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.